ÂÜÀòÂÒÂ×

Dr. Gary Ward has served as Quince Therapeutics’ Vice President, CMC Management since August 2022. To this role he brings 30 years of experience in managing chemistry, manufacturing, and controls and product development operations for a broad range of NCE types and product dosage forms. Previously, Dr. Ward was the founder of Ward Consulting, LLC, a boutique CMC consulting firm where he spent the past 12 years. During his tenure as a consultant, Dr. Ward led CMC efforts on numerous IND stage compounds as well as several late-stage candidates resulting in commercial approval, including Lumeblue® (methylene blue), Aemcolo® (rifamycin), Byfavo® (remimazolam), and Vabomere® (meropenem/vaborbactam). Earlier in his career, he managed CMC efforts for several firms, including Pfizer, Dura Pharmaceuticals, Chugai Biopharmaceuticals, and 3M Company, resulting in the commercialization of Actemra® (tocilizumab), Proventil HFA (albuterol sulfate), and QVAR® (beclomethasone dipropionate). Dr. Ward holds several patents in the area of formulation and drug delivery. He received his Ph.D. in Pharmaceutical Sciences from the University of Arizona in 1992.